Genecis Bio
+40%
est. 2Y upside i
Makes guilt-free plastics from food waste
Rank
#1207
Sector
Biotechnology
Est. Liquidity
~4Y
Data Quality
Data: MediumThe equity offers a 40% expected upside over 2 years, but with high risk from incumbents and preference overhang.
Last updated: July 3, 2026
If Genecis capitalizes on its low-cost PHA production and gains large contracts, revenue could reach $18.2M with an 8x multiple, yielding 204% upside. IPO catalyst could expand multiple further.
Revenue grows to $18.2M with a 5x multiple in line with public comps, providing 82% upside before preference drag.
Competitive pressure from incumbents and slower adoption lead to a 2x multiple on $18.2M revenue, resulting in -39% upside after dilution.
Preference Stack Risk
severeFunding Intensity
71%$32M in preference on a $45M valuation leaves common stock only $13M of value.
Dilution Risk
moderateLikely dilution from future funding rounds given capital needs, estimated 15-25%.
Secondary Liquidity
noneNo secondary trading activity reported.
Questions to Ask at the Interview
Strategic questions based on Genecis Bio's data — designed to show you've done your homework.
- 1
“How does Genecis plan to scale its waste-to-PHA production to compete with petroleum-based plastics on cost?”
- 2
“What is the gross margin trend, and how does the asset-light partnership model affect unit economics?”
- 3
“Given the preference overhang (71%), what is the realistic common stock value at exit scenarios?”
Community
Valuation Sentiment
Our model estimates +40% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.